Tracking Early Markers of Progression in Neurodegenerative Diseases
Follows people with neurodegenerative diseases, such as Parkinson disease, through routine checkups over time.
Plain-language title generated from the registry record
Registry title: Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
Key facts
- Where
- Cassino, ItalySee the site
Where in Italy
- San Raffaele CassinoCassino, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Casa di Cura San Raffaele Cassino
- Trial code
- NCT06596746
- Record updated
- 2 September 2026
- Original description
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.Read full original descriptionShow less
Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study
MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.
Inclusion: Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders; Patients with diagnosis of Parkinson's Disease; Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank; Diagnosis of Movement Disorder not related to Parkinson's Disease; Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy; Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy; Diagnosis of Essential Tremor; Willing to participate in the study, understand the procedures and sign the informed consent; Patients affected by cognitive impairment (CI) and dementia; Diagnosis of probable:; Lewy Body Dementia; Alzheimer's Disease; Mild Cognitive Decline; Subjective memory complaints; Willing to participate in the study, understand the procedures and sign the informed consent.
Exclusion: There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.